



NEWS RELEASE

## CRINETICS PHARMACEUTICALS TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

2024-08-29

SAN DIEGO – August 29, 2024 – **Crinetics Pharmaceuticals, Inc.** (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in fireside chats at the Morgan Stanley 22<sup>nd</sup> Annual Global Healthcare Conference and the Cantor Global Healthcare Conference both being held in New York, NY in September.

Morgan Stanley 22<sup>nd</sup> Annual Global Healthcare Conference  
Fireside chat on Wednesday, September 4, 2024 at 5:35 p.m. Eastern Time

Webcast link [HERE](#)

Cantor Global Healthcare Conference  
Fireside chat on Wednesday, September 18, 2024 at 8:35 a.m. Eastern Time

Webcast link [HERE](#)

The live and archived webcasts will be accessible on the Events & Presentations page in the Investors section of the Crinetics' website at [www.crinetics.com/events](http://www.crinetics.com/events).

If you are interested in arranging a 1×1 meeting with management, please contact your conference representative.

## ABOUT CRINETICS PHARMACEUTICALS

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, **paltusotine**, is an investigational, first-in-class, oral, once-daily somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for acromegaly and in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing **atumelnant** (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. All of the company's drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

---

### Investors:

Gayathri Diwakar

Head of Investor Relations

**[gdiwakar@crinetics.com](mailto:gdiwakar@crinetics.com)**

**(858) 345-6340**

### Media:

Natalie Badillo

Head of Corporate Communications

**[nbadillo@crinetics.com](mailto:nbadillo@crinetics.com)**

**(858) 345-6075**

Source: Crinetics Pharmaceuticals, Inc.